High-frequency interferon-γ-secreting splenocytes specific for murine cytomegalovirus immediate-early-1 (IE-1) peptide 168YPHFMPTNL176 are insufficient to provide complete protection from viral challenge

Journal of Medical Virology

Volumn 69, Issue 2, 2003, Pages 240-250

  Morley, Peter J ^b   Ertl, Peter F ^c   Sweet, Clive ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b GLAXOSMITHKLINE   (United Kingdom)

^c NONE

Author keywords

High frequency IFN secreting splenocytes; Human cytomegalovirus; Peptide 168YPHFMPTNL176

Indexed keywords

GAMMA INTERFERON; PCDNA89 VACCINE; PEPTIDE DERIVATIVE; TYROSYLLEUCYLASPARTYLPHENYLALANYLMETHIONYLPROLYLPROLYLASPARAGYLLEUCINE; TYROSYLPROLYLHISTIDYLPHENYLALANYLMETHIONYLPROLYLPROLYLSERYLLEUCINE; TYROSYLPROLYLHISTIDYLPHENYLALANYLMETHIONYLPROLYLTHREONYLASPARAGYLLEUCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; CYTOTOXIC T LYMPHOCYTE; DNA SEQUENCE; FEMALE; GENE TARGETING; IMMEDIATE EARLY GENE; INFECTION PREVENTION; MOUSE; NONHUMAN; PLASMID; RAT; SPLEEN CELL; TEMPERATURE SENSITIVE MUTANT; VIROLOGY; VIRUS IMMUNITY; VIRUS STRAIN;

3T3 CELLS; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; CYTOMEGALOVIRUS VACCINES; HERPESVIRIDAE INFECTIONS; IMMEDIATE-EARLY PROTEINS; IMMUNIZATION; INTERFERON TYPE II; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUROMEGALOVIRUS; PEPTIDES; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TRANS-ACTIVATORS; VACCINES, DNA;

CYTOMEGALOVIRUS; HUMAN HERPESVIRUS 5; MAIZE CHLOROTIC MOTTLE VIRUS; MOUSE CYTOMEGALOVIRUS 1; MURINAE;

EID: 12244310553     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.10272     Document Type: Article

References (53)

1. Akel HMO, Sweet C. 1993. Isolation and preliminary characterisation of twenty-five temperature-sensitive mutants of mouse cytomegalovirus. FEMS Microbiol Lett 113:253-260.
2. Andre S, Seed B, Eberle J, Schraut W, Bultmann A, Haas J. 1998. Increased immune response elicited by DNA vaccination with a synthetic gp120 sequence with optimized codon usage. J Virol 72: 1497-1503.
3. Bennett AM, Phillpotts RJ, Perkins SD, Jacobs SC, Williamson ED. 1999. Gene gun mediated vaccination is superior to manual delivery for immunisation with DNA vaccines expressing protective antigens from Yersiniapestis or Venezuelan Equine Encephalitis virus. Vaccine 18:588-596.
4. Bevan IS, Sammons CC, Sweet C. 1996. Investigation of murine cytomegalovirus latency and reactivation in mice using viral mutants and the polymerase chain reaction. J Med Virol 48:308- 320.
5. Boppana SB, Britt WJ. 1995. Antiviral antibody responses and intrauterine transmission after primary maternal cytomegalovirus infection. J Infect Dis 171:1115-1121.
6. Britt WJ. 1996. Vaccines against human cytomegalovirus: time to test. Trends Microbiol 4:34-38.
7. Charini WA, Kuroda MJ, Schmitz JE, Beaudry KR, Lin W, Lifton MA, Krivulka GR, Necker A, Letvin NL. 2001. Clonally diverse CTL response to a dominant viral epitope recognizes potential epitope variants. J Immunol 1679:4996-5003.
8. Collins EJ, Booth BL Jr, Cerundolo V. 1999. Extensive alanine substitutions increase binding affinity of an influenza nucleoprotein peptide to HLA-Aw68 and do not abrogate peptide-specific CTL recognition. J Immunol 162:331-337.
9. Deayton J, Mocroft A, Wilson P, Emery VC, Johnson MA, Griffiths PD. 1999. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy. AIDS 13:1203-1206.
10. Degano P, Sarphie DF, Bangham CR. 1998. Intradermal DNA immunization of mice against influenza A virus using the novel PowderJect system. Vaccine 16:394-398.
11. Del Val M, Volkmer H, Rothbard JB, Jonjic S, Messerle M, Schickedanz J, Reddehase MJ, Koszinowski UH. 1988. Molecular basis for cytolytic T-lymphocyte recognition of the murine cytomegalovirus immediate-early protein pp89. J Virol 62:3965-3972.
12. Eisenlohr LC, Bacik I, Bennink JR, Bernstein K, Yewdell JW. 1992. Expression of a membrane protease enhances presentation of endogenous antigens to MHC class I-restricted T lymphocytes. Cell 71:963-972.
13. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG, Freeman R, Rohrer R. 1997. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. Clin Transplant 11:432-437.
14. + T cell clones specific for a mouse cytomegalovirus epitope. Virology 255:40-49.
15. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. 1992. The outcome of congenital cytomegalovirus (CMV) infection in relation to maternal antibody status. N Engl J Med 326:663-667.
16. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency disease treated with zidovudine. J Infect Dis 166:1223-1227.
17. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. 1998a. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 187:1647-1657.
18. Gallimore A, Hombach J, Dumrese T, Rammensee HG, Zinkernagel RM, Hengartner HA. 1998b. Protective cytotoxic T cell response to a subdominant epitope is influenced by the stability of the MHC class I/peptide complex and the overall spectrum of viral peptides generated within infected cells. Eur J Immunol 28: 3301-3311.
19. Gill TA, Morley PJ, Sweet C. 2000. Replication-defective mutants of mouse cytomegalovirus protect against wild-type virus challenge. J Med Virol 62:127-139.
20. Gonzalez Armas JC, Morello CS, Cranmer LD, Spector DH. 1996. DNA immunization confers protection against murine cytomegalovirus infection. J Virol 70:7921-7928.
21. Goulder PJ, Addo MM, Altfeld MA, Rosenberg ES, Tang Y, Govender U, Mngqundaniso N, Annamalai K, Vogel TU, Hammond M, Bunce M, Coovadia HM, Walker BD. 2001. Rapid definition of five novel HLA-A*3002-restricted human immunodeficiency virus-specific cytotoxic T-lymphocyte epitopes by ELISPOT and intracellular cytokine staining assays. J Virol 75:1339-1347.
22. Gyulai Z, Endresz V, Burian K, Pincus S, Toldy J, Cox WI, Meric C, Plotkin S, Gonczol E, Berencsi K. 2000. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IEl-specific CTLs. J Infect Dis 181:1537-1546.
23. Holtappels R, Thomas D, Podlech J, Geginat G, Steffens HP, Reddehase MJ. 2000. The putative natural killer decoy early gene m04 (gp34) of murine cytomegalovirus encodes an antigenic peptide recognized by protective antiviral CD8 T cells. J Virol 74:1871-1884.
24. Holtappels R, Podlech J, Grzimek NK, Thomas D, Pahl-Seibert MF, Reddehase MJ. 2001. Experimental pre-emptive immunotherapy of murine cytomegalovirus disease with CD8 T-Cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein. J Virol 75:6584-6600.
25. Holtappels R, Thomas D, Podlech J, Reddehase MJ. 2002. Two antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotypes. J Virol 76:151-164.
26. Jouan M, Saves M, Tubiana R, Carcelain G, Cassoux N, Aubron-Olivier C, Fillet AM, Nciri M, Senechal B, Chene G, Tural C, Lasry S, Autran B, Katlama C, and the RESTIMOP study team. 2001. Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 15:23-31.
27. Kemble G, Duke G, Winter R, Spaete R. 1996. Defined large-scale alteration of the human cytomegalovirus genome constructed by cotransfection of overlapping cosmids. J Virol 70:2044-2048.
28. +-T-cell response to human cytomegalovirus: the 72-kilodalton major immediate-early protein revisited. J Virol 73:8179-8184.
29. Larregina AT, Watkins SC, Erdos G, Spencer LA, Storkus WJ, Beer Stolz D, Falo LD Jr. 2001. Direct transfection and activation of human cutaneous dendritic cells. Gene Ther 8:608-617.
30. Lewicki HA, von Herrath MG, Evans CF, Whitton JL, Oldstone MB. 1995. CTL escape viral variants. II. Biologic activity in vivo. Virology 211:443-450.
31. Lucin P, Pavic I, Polic B, Jonjic S, Koszinowski UH. 1992. Gamma-interferon-dependent clearance of cytomegalovirus-infection in salivary glands. J Virol 66:1977-1984.
32. + T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition. J Gen Virol 77:2615-2623.
33. Melby PC, Ogden GB, Flores HA, Zhao W, Geldmacher C, Biediger NM, Ahuja SK, Uranga J, Melendez M. 2000. Identification of vaccine candidates for experimental visceral leishmaniasis by immunization with sequential fractions of a cDNA expression library. Infect Immun 68:5595-5602.
34. Mocarski ES. 1996. Cytomegaloviruses and their replication. In: Fields BN, Knipe DM, Howley PM, editors. Virology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins.
35. Morello CS, Cranmer LD, Spector DH. 2000. Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65). J Virol 74:3696-3708.
36. Morley PJ, Ertl P, Sweet C. 2002. Immunisation of Balb/c mice with severely attenuated murine cytomegalovirus mutants induces protective cellular and humoral immunity. J Med Virol 67:187-199.
37. Ossendorp F, Eggers M, Neisig A, Ruppert T, Groettrup M, Sijts A, Mengede E, Kloetzel PM, Neefjes J, Koszinowski UH, Melief C. 1996. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 5:115-124.
38. Plotkin SA, Friedman HM, Fleisher GR, Dafoe DC, Grossman RA, Smiley ML, Starr SE, Wlodaver C, Friedman AD, Barker CF. 1984. Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplant. Lancet 1:528-530.
39. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE. 1989. Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159:860-865.
40. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K. 1990. Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis 12:827-838.
41. Plotkin SA, Higgins R, Kurtz JB, Morris PJ, Campbell DA, Shope TC, Spector SA, Danker WN. 1994. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipi-ents. Transplantation 58:1176-1178.
42. Potter P, Tourdot S, Blanchard T, Smith GL, Gould KG. 2001. Differential processing and presentation of the H-2D(b)-restricted epitope from two different strains of influenza virus nucleoprotein. J Gen Virol 82:1069-1074.
43. Reddehase MJ, Koszinowski UH. 1991. Redistribution of critical major histocompatibility complex and T cell receptor-binding functions of residues in an antigenic sequence after biterminal substitution. Eur J Immunol 21:1697-1701.
44. Reusser P, Cathomas G, Attenhofer R, Tamm M, Thiel G. 1999. Cytomegalovirus (CMV)-specific T cell immunity after renal transplantation mediates protection from CMV disease by limiting the systemic virus load. J Infect Dis 180:247-253.
45. Rininsland FH, Helms T, Asaad RJ, Boehm BO, Tary-Lehmann M. 2000. Granzyme B ELISPOT assay for ex vivo measurements of T cell immunity. J Immunol Methods 240:143-155.
46. Sammons CC, Sweet C. 1989. Isolation and preliminary characterisation of temperature-sensitive mutants of mouse cytomegalovirus of differing virulence for 1-week old mice. J Gen Virol 70:2373-2381.
47. Scheibenbogen C, Romero P, Rivoltini L, Herr W, Schmittel A, Cerottini JC, Woelfel T, Eggermont AM, Keilholz U. 2000. Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELI-SPOT assay and chromium-release assay: a four-centre comparative trial. J Immunol Methods 240:81-89.
48. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, Veren DA, Page F, Alford CA. 1986. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA 256:1904-1908.
49. Stratton KR, Durch JS, Lawrence RS. 1999. Vaccines for the 21st century: a tool for decision making. Institute of Medicine Report. Washington, DC: National Academy Press.
50. van Der Bij W, Speich R. 2001. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis 33(suppl 1):S32-37.
51. Whitley RJ, Jacobson MA, Friedberg DN, Holland GN, Jabs DA, Dieterich DT, Hardy WD, Polis MA, Deutsch TA, Feinberg J, Spector SA, Walmsley S, Drew WL, Powderly WG, Griffiths PD, Benson CA, Kessler HA. 1998. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med 158: 957-969.
52. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG. 1996. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70:7569-7579.
53. Zaia JA, Gallez-Hawkins G, Li X, Yao ZQ, Lomeli N, Molinder K, La Rosa C, Diamond DJ. 2001. Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates. J Virol 75:2472-2474.